Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

SIMPLE SUMMARY: The treatment of renal cancer is currently based on the use of antiangiogenic drugs targeting the VEGF-A pathway and/or immunotherapy targeting immune checkpoint inhibitors. Despite combined therapies being approved as first-line treatments, all patients will not benefit from them. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillaume, Zoé, Auvray, Marie, Vano, Yann, Oudard, Stéphane, Helley, Dominique, Mauge, Laetitia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776425/
https://www.ncbi.nlm.nih.gov/pubmed/36551652
http://dx.doi.org/10.3390/cancers14246167